A Spirituality-Based Intervention Improves Blood Pressure Control and Central Hemodynamics: The FEEL Trial
Key Points: HTN is a leading cause of cardiovascular (CV) morbidity and mortality worldwide, but blood pressures remain uncontrolled worldwide. Spirituality, a comprehensive... Read more.
Advancing Acute MI Care in Densely Populated LMICs: Innovative Standalone Chest Pain Units for Expedited Triage and Timely Management – A Role Model for Global Healthcare Systems
Key Points: The burden of coronary artery disease (CAD) is high in South Asia, but challenges are present with time-sensitive cardiac care, as evidenced within... Read more.
Simultaneous Team-Based Remote Education and Medication Titration Increases Diabetes Medication Prescription Compared to a Sequential Approach: The Diabetes Remote Intervention to ImproVe Use of Evidence-based Medications (DRIVE) Study
Key Points: Despite demonstrated effectiveness of many SGLT2-inhibitors and GLP-1 agonists at improving both cardiovascular (CV) and kidney outcomes, utilization... Read more.
No Benefit of Long-Term Beta-Blockers after MI with Preserved EF: REDUCE AMI Trial
Key Points -Beta blocker therapy in patients with acute MI is the current standard of care, but we lack clinical trials testing this concept in the era of PCI and... Read more.
TACT2: Chelation therapy with EDTA does not improve cardiovascular outcomes in post-MI patients with diabetes
Key Points: EDTA is a highly effective chelator of the ubiquitous pollutants lead and cadmium, both of which are associated with elevated cardiovascular risk. ... Read more.
ULTIMATE-DAPT: De-escalating to ticagrelor alone after 1 month reduced bleeding without an increase in ischemic events compared to continuous DAPT through 1 year
Key Points: The optimal time to de-escalate from DAPT to SAPT following PCI with modern DES after ACS is uncertain. The ULTIMATE-DAPT study found that transitioning... Read more.
LIBerate-HR Trial: Lerodalcibep, A Small-Binding Protein Based PCSK9 Inhibitor Administered Monthly Significantly Lowered LDL-C
Key Points – Newer cholesterol guidelines advise lower target values for LDL-C for high-risk patients, yet many patients do not reach this goal on statin... Read more.
BRIDGE-TIMI 73a Trial: Olezarsen significantly reduces triglyceride levels among patients with hypertriglyceridemia and elevated CV risk
Key Points: Olezarsen is an antisense oligonucleotide which targets messenger RNA for apolipoprotein C-III (APOC3), a lipoprotein which up-regulates triglyceride... Read more.
Mandibular Advancement Device (MAD) Therapy Non-Inferior to CPAP for Blood Pressure Reduction In OSA And High CV Risk: The CRESCENT Trial
Key Points: Hypertension (HTN) guidelines recommend treating obstructive sleep apnea (OSA) in such patients, though data on BP reduction for mandibular advancement... Read more.
Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Mellitus
Key Points: There is uncertainty determining who is likely to develop dysglycemia and type 2 diabetes mellitus (T2DM) due to weight gain and adiposity: 80% of those... Read more.